{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.2","upperLimit":"11.8","value":"7.6"},{"groupId":"OG001","lowerLimit":"3.0","upperLimit":"7.5","value":"5.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"93"}],"units":"Participants"}],"description":"Defined as the time from the date of randomization to the date of documented disease progression.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Tucatinib in combination with capecitabine \\& trastuzumab","id":"OG000","title":"Tuc+Cap+Tra"},{"description":"Placebo in combination with capecitabine \\& trastuzumab","id":"OG001","title":"Pbo+Cap+Tra"}],"paramType":"MEDIAN","populationDescription":"ITT-PFSBrainMets population: included all randomized participants with brain metastases (evaluated by their random treatment assignment).","reportingStatus":"POSTED","timeFrame":"34.6 months","title":"PFS in Patients With Brain Metastases at Baseline Using RECIST 1.1 as Determined by BICR","type":"SECONDARY","unitOfMeasure":"months"}